Boston Scientific (NYSE: BSX) disclosed on 26 August 2026 that a cybersecurity incident identified the previous day has disrupted its global operations, including order processing and shipping. The company said in a filing with the US Securities and Exchange Commission that the investigation is ongoing.
Shares fell 5.03% to $46.90, a fresh 20-day low, according to Reuters. The stock had traded as high as $53.55 over the past 20 sessions.
What the filing says
Boston Scientific identified the incident on 25 August and activated its incident response protocols, bringing in third-party cybersecurity experts to assess and contain the threat, the company said in its 8-K. The disruption has affected access to information systems and business applications that support operations, including the ability to process and ship customer orders, and the company said it does not yet know when full restoration would be complete.
Crucially, the filing stops short of calling the incident material. Boston Scientific said the full scope, nature and impacts of the breach, including any financial consequences, are not yet known, and that it has not yet determined whether the incident is reasonably likely to have a material impact on the company.
Cork staff sent home as outage spreads
The disclosure’s careful language contrasts with events on the ground. Staff at Boston Scientific’s Cork, Ireland plant, part of a workforce exceeding 7,000 people in the country, were sent home with full pay as teams worked to restore network communications worldwide, according to the Irish Examiner. A company spokesperson told MassDevice that Boston Scientific was experiencing a global network outage and was working to understand its impact and restore normal operations.
Reuters reported shares fell as much as 3.5% in premarket trading before the decline extended through the session. CNBC separately confirmed the attack had disrupted the company’s access to information systems, including shipment services, citing the SEC filing. Dow Jones Newswires reported the hack was hampering Boston Scientific’s ability to fill customer orders, with the company still unable to quantify operational or financial impact.
A scaled business facing an unquantified hit
The disruption lands on a business that has grown steadily in recent years. Boston Scientific’s quarterly revenue rose from $3.856bn in the first quarter of 2024 to $5.442bn in the second quarter of 2026, according to SEC filings. Diluted earnings per share climbed over the same period from $0.33 to $0.61, filings show, underscoring the scale of order volumes an extended shipping disruption could touch.
The company’s most recent quarters show a consistent upward trajectory: EPS of $0.45 in the first quarter of 2025 and $0.53 in the second, followed by $0.90 in the first quarter of 2026 ahead of the $0.61 posted for the three months to June, according to the same filings. Revenue for the first quarter of 2026 stood at $5.203bn, itself up from $4.663bn a year earlier, reflecting the growth base against which any disruption to order processing would be measured.
The share price move also compounds an already difficult year for the stock. The company had already seen significant declines earlier in 2026 tied to a weaker profit forecast, according to reporting cited by Pluang News, meaning Wednesday’s cyberattack disclosure adds to existing investor uncertainty rather than landing against a stable backdrop.
No sign of unusual pre-disclosure trading
FINRA short-volume data for BSX in the ten sessions to 25 August show the daily short-sale ratio ranging between 0.326 and 0.720, with the reading on the day before disclosure at 0.499, according to FINRA figures in the pack. Nothing in that range points to an unusual spike ahead of the announcement.
Trading volume on the day of disclosure ran close to the 20-day average, the pack shows, even as the stock touched its lowest level in that window. Broader market conditions were largely stable around the disclosure: the 10-year US Treasury yield stood at 4.70% on 24 August against 4.74% previously, and the 2-year yield held flat at 4.24%, according to Federal Reserve Bank of St. Louis data, suggesting the stock’s move was company-specific rather than macro-driven.
Irish media coverage has framed the incident as part of a broader pattern of cyberattacks targeting multinational health-sector companies, according to EchoLive.ie. Boston Scientific has not given a timeline for full restoration of its systems, and the company’s own disclosure leaves open whether the incident will ultimately be judged material to its financial results.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
